Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial
- DOI
- 10.3389/fpubh.2026.1918118
- Published
- 2026-08-27
- Container
- Frontiers in Public Health
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fpubh.2026.1918118,
title = {Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial},
author = {Rui Feng and Ping Liang and Yajing Wang and Dong Li and Huixian Jia and Ying Zheng and Liman Huo and Qi Lv},
year = {2026},
journal = {Frontiers in Public Health},
doi = {10.3389/fpubh.2026.1918118},
url = {https://doi.org/10.3389/fpubh.2026.1918118}
}RIS
TY - JOUR TI - Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial AU - Rui Feng AU - Ping Liang AU - Yajing Wang AU - Dong Li AU - Huixian Jia AU - Ying Zheng AU - Liman Huo AU - Qi Lv PY - 2026 JO - Frontiers in Public Health DO - 10.3389/fpubh.2026.1918118 UR - https://doi.org/10.3389/fpubh.2026.1918118 ER -
APA
Feng, R., Liang, P., Wang, Y., Li, D., Jia, H., Zheng, Y., Huo, L., & Lv, Q. (2026). Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1918118
Source records
- crossref · retrieved 2026-09-26T12:05:01.025Z